Medivir AB (MVIRb.F) Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders
10/9/2013 9:31:01 AM
Stockholm, Sweden – Medivir AB (OMX:MVIR) announced further results from the
phase I clinical study on the investigational cathepsin K inhibitor MIV-711 for
the treatment of osteoarthritis and other bone related disorders. The 7 day data
was presented on October 6th at the American Society for Bone and Mineral
Research (ASBMR) Annual Meeting in Baltimore, USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by